Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Corcept Presents New Data at ASCO 2026: Lifyorli Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
CoTec Holdings Corp. Notes HyProMag USA Deployment of Mobile Inserma System, Extending Hard Disk Drive Processing to Customer Sites Across the United States
Renforth Successfully Intersects Gold in Both Drillholes Undercutting Surface Gold Results within the 2025 MRE Pit Shell at Wholly Owned Parbec Gold Deposit in Malartic, Quebec
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
Heliostar Reports 52.4m Grading 5.84 g/t Gold from the High Grade Panel and Continues to Build Out the Expansion Zone at Ana Paula
